对前列腺动脉栓塞的栓塞颗粒进行比较,以治疗患有良性前列腺增生症的患者下泌尿道症状
Tiago Bilhim1,2, Nuno Vasco Costa3,4, Daniel Torres3,4
1Interventional Radiology Unit, Curry Cabral Hospital, Unidade Local de Saúde São José; Centro Clínico Académico de Lisboa, Lisboa, Portugal. tiagobilhim@hotmail.com.
European radiology
|August 6, 2024
概括
使用聚乙烯醇颗粒 (PVA),包围体或包围体进行前列腺动脉栓塞 (PAE) 证明在治疗良性前列腺激增症 (BPH) 中具有同等的安全性和有效性. 这些栓塞剂在下泌尿道症状上显示出相似的改善,并且在不良事件或再干预率上没有显著差异.
科学领域:
- 干预性放射学 干预性放射学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 血管栓塞是因为血管栓塞.
背景情况:
- 良性前列腺增生 (BPH) 是一种常见的疾病,导致下泌尿道症状 (LUTS).
- 前列腺动脉栓塞 (PAE) 是BPH的有效的微创治疗方法.
- 对PAE的栓塞剂的选择可能会影响结果,需要进行比较研究.
研究的目的:
- 为了比较三个不同的栓塞剂的安全性和有效性 - - 聚乙醇颗粒 (PVA),三糖凝微球 (Embospheres) 和涂有聚-F (Embozenes) 的水凝微球 - - 对于BPH患者的PAE.
主要方法:
- 2019年至2023年的一项单中心前性队列研究包括153名BPH患者 (IPSS ≥15或QoL ≥4).
- 患者按时间顺序分配,接受PVA (100-300μm,n=53),包裹球 (300-500μm,n=50) 或包裹球 (400μm,n=50).
- 包括IPSS,QoL,峰值尿流量,空虚后残留体积,前列腺体积,PSA,不良事件和重新干预率在基线和PAE后1个月和6个月的评估结果.
主要成果:
- 在这三个组中,在轻微或重大不良事件中没有发现显著差异.
- 所有的结果指标,包括IPSS/QoL得分,在所有组中都显示出与基线相比显著改善,在6个月后,PVA,Embospheres和Embozenes之间没有统计学上显著的差异.
- 6个月后的再干预率是可比的:PVA的9%,Embospheres的14%,Embozenes的8% (p=0.591).
结论:
- 使用PVA颗粒,包膜或包膜的PAE在治疗BPH相关的LUTS中同样安全和有效.
- 这项研究提供了第一个前性证据,证明这些常用于PAE的栓塞剂之间的等价性.
- 这些发现表明,不同的栓塞性颗粒可以互换地用于PAE,具有一致的临床结果和安全性.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
164
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
164
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
147
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
147
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
140
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
140